Archive for Publications

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Overall Survival Results of BRIA-IMT Allogenic Whole Cell-Based Cancer Vaccine

A Phase 1, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 (4-1BB x PD-L1 BsAb) in Patients with Advanced or Metastatic Solid Tumors

Comparative Assessment of Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK210(EGFR) to ex vivo Diakine Response Assay

First-in-Human Results of STX-478, A Mutant-Selective PI3Ka Inhibitor, in HR+ Breast Cancer and Advanced Solid Tumor Patients

Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity

A phase 1 multicenter study of the safety and efficacy of the NKG2A targeting antibody S095029 as single agent and in combination with anti-PD1 in patients with advanced malignancies

DRAGON Trial: Durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor resistant advanced cancers